Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serabelisib + Canagliflozin in Advanced Solid Tumors
NCT04073680Phase 2Unknown
- Sponsor
- Petra Pharma Corporation
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of serabelisib in breast cancer, endometrial cancer (EC), lung cancer, colorectal cancer (CRC), head and neck cancer (HNC), sponsored by Petra Pharma Corporation. Status: unknown.
02
Drugs
serabelisib
03
Conditions
breast cancerendometrial cancer (EC)lung cancercolorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04073680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073680.